Dusigitumab
From Wikipedia the free encyclopedia
 | This article needs additional citations for verification. (February 2023) |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IGF2 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6372H9824N1700O2016S54 |
| Molar mass | 144233.81 g·mol−1 |
Dusigitumab is a human monoclonal antibody designed for the treatment of cancer. It binds to IGF2.[1][2] It was developed by MedImmune, which was acquired by AstraZeneca, using Xenomouse technology licensed from Abgenix.[3] Its development has been discontinued.[2]
References[edit]
- ^ "Dusigitumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.
- ^ a b Osher E, Macaulay VM (August 2019). "Therapeutic Targeting of the IGF Axis". Cells. 8 (8): 895. doi:10.3390/cells8080895. PMC 6721736. PMID 31416218.
- ^ "Dusigitumab - MedImmune". AdisInsight. Springer Nature Switzerland AG.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |